New Media Consumer Opinions – Breast Cancer Chemotherapy is an indication-specific, quarterly updated series of reports that is designed to provide clients with online consumer opinions, sentiments, and attitudes about breast cancer chemotherapy treatment.
Introduction
Breast cancer stakeholders in the US are very active in online communities - sharing information, experiences, and emotions. This report looks at perceptions of products, treatment regimens, the disease, and quality of life issues as expressed by breast cancer stakeholders in major US online communities and forums.
Scope of This Report
- 740,999 stakeholder opinions from 35,969 unique online users
- Volume and quality of overall opinion is reviewed in both single therapy and combination therapy regimens
- Emotional scores are evaluated for each of the key drugs used in the treatment of breast cance
- Specific stakeholder sentiments are compared across major drugs
Key Highlights
Medium volume of discussion for Avastin (bevacizumab) reflects more recent FDA approval for BC (2008) and shorter length of larger volume utilization in BC; similarly for the taxane Abraxane® (protein-bound paclitaxel) – which still is not used widely due to availability of generic taxanes. Opinion is far more positive than negative.
Tykerb® (lapatinib) generates less discussion, likely because it is indicated and used later in the line of therapy (post trastuzumab failure). Discussion tilts positive.
Recently, the FDA has called for removal of bevacizumab from the market due to concerns about side effects (particularly stroke). In response there has been a great deal of patient pushback. If this dynamic continues, we would expect the next update of this report to show bevacizumab moving in a direction of intense support for keeping bevacizumab ‘on the market,’ i.e., retaining its BC indication.
Reasons to Purchase
- Identify stakeholders’ perceptions of products, treatment regimens, and their experience with breast cancer.
- Evaluate product performance across a variety of emotional dimensions including perceptions of quality, effectiveness, and brand allegiance.
- Understand current trends in stakeholder thinking and identify patterns that may assist in future product development and launch strategy.
